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Abstract
Background: The respiratory epithelium is a major portal of entry for pathogens and employs
innate defense mechanisms to prevent colonization and infection. Induced expression of human β-
defensin 2 (HBD2) represents a direct response by the epithelium to potential infection. Here we
provide evidence for the critical role of Toll-like receptor 4 (TLR4) in lipopolysaccharide (LPS)-
induced HBD2 expression by human A549 epithelial cells.
Methods: Using RTPCR, fluorescence microscopy, ELISA and luciferase reporter gene assays we
quantified interleukin-8, TLR4 and HBD2 expression in unstimulated or agonist-treated A549 and/
or HEK293 cells. We also assessed the effect of over expressing wild type and/or mutant TLR4,
MyD88 and/or Mal transgenes on LPS-induced HBD2 expression in these cells.
Results: We demonstrate that A549 cells express TLR4 on their surface and respond directly to
Pseudomonas LPS with increased HBD2 gene and protein expression. These effects are blocked by
a TLR4 neutralizing antibody or functionally inactive TLR4, MyD88 and/or Mal transgenes. We
further implicate TLR4 in LPS-induced HBD2 production by demonstrating HBD2 expression in
LPS non-responsive HEK293 cells transfected with a TLR4 expression plasmid.
Conclusion: This data defines an additional role for TLR4 in the host defense in the lung.
Introduction
The lung represents the largest epithelial surface in the
body and is a major portal of entry for pathogenic micro-
organisms. It employs a number of efficient defense
mechanisms to eliminate airborne pathogens encoun-
tered in breathing, including the specific innate and adap-
tive immune responses, which represent a dynamic
interaction of host and pathogen. Lipopolysaccharide
(LPS) is an important antigenic component of Gram-neg-
ative bacteria, and is a potent stimulus to local and sys-
temic immune responses. The human receptor for LPS is
Toll-like-receptor 4 (TLR4) [1].
TLRs are a family of pattern recognition receptors whose
pivotal importance in orchestrating the innate immune
response is widely accepted. Binding of ligand activates a
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signaling cascade involving TRAF6, IKKs and I-κBs, culmi-
nating in NF-κB translocation to the nucleus [1]. NF-κB
regulates the inducible expression of cytokines, chemok-
ines, adhesion molecules and acute phase proteins which
activate cellular immune responses [2]. TLR signaling
pathways arise from intracytoplasmic Toll/IL-1 receptor
(TIR) domains, which are conserved among TLRs and TIR
domain-containing adaptor proteins such as MyD88,
Mal/TIRAP and TRIF/TICAM-1. These adaptor proteins
confer specificity on TLR signaling, with Mal specifically
involved in MyD88-dependent signaling via TLR2 and
TLR4, and TRIF in the MyD88-independent TLR3- and
TLR4- signaling [3]
The mammalian innate immune system produces a vari-
ety of anti-microbial peptides (AMPs) as part of its host
defense repertoire. The defensins are a broadly dispersed
group of AMPs, and are classified according to their
molecular structure into three distinct families: the α-, β-
and the θ-defensins. Unlike α-defensins, which are pro-
duced mainly by neutrophils, β-defensins are produced
directly by epithelial cells, and combat infection both
through direct microbicidal action and by modulation of
cell-mediated immunity [4-7]. To date, four human β-
defensins (HBD) have been identified (HBD1-4),
although genomic studies suggest more have yet to be dis-
covered [8,9]. In contrast to HBD1, which is constitutively
and stably expressed, HBD2 expression is induced in
response to infective stimuli, including Gram-negative
and, less potently, Gram-positive bacteria or their compo-
nents or to proinflammatory stimuli including tumor
necrosis factor α (TNFα) and interleukin-1β (IL-1β) in
vitro [10,11].
Like other defensins, HBD2 has a broad spectrum of anti-
microbial activity, displaying potent microbicidal activity
against many Gram-negative bacteria and less potent bac-
teriostatic activity against Gram-positive bacteria [11]. It
has recently been demonstrated that activation of TLR2 by
bacterial lipoprotein results in up regulation of HBD2 in
tracheobronchial epithelium [12]. LPS and Gram-nega-
tive bacteria such as mucoid P. aeruginosa are a more
potent stimulus for HBD2 production, which in turn has
anti-bacterial activity predominantly against Gram-nega-
tive bacteria. Colonisation and infection due to Gram-
negative bacteria are important in many pulmonary dis-
eases including severe COPD [13] and Cystic Fibrosis
[14]. Production of HBD2 by respiratory epithelium is an
important component of host defense against Gram-neg-
ative organisms, and understanding of the signaling path-
ways involved may further our understanding of and
guide future therapeutic strategies in these diseases.
Cultured intestinal epithelial cells have been shown to
produce HBD2 in response to LPS following transfection
with TLR4 and MD2 [15]. Although CD-14 is known to be
critical to LPS-induced HBD2 production in airway epi-
thelium [16], the role of TLR4 in transcriptional regula-
tion of HBD2 in respiratory epithelium has not been
established. Indeed, the importance of the respiratory epi-
thelium in the innate immune response to LPS has been
called into question by some recent publications [17,18].
In this study we demonstrate TLR4 expression in A549
pulmonary epithelial cells and production of HBD2 in
response to LPS. We examine the effect of modulation of
TLR4 by receptor blockade and expression of a dominant
negative TLR4 construct on induced expression of HBD2.
We show that LPS-unresponsive HEK293 cells can pro-
duce HBD2 in response to LPS following transfection with
TLR4 and MD2 transgenes and demonstrate that the adap-
tor proteins MyD88 and Mal are involved in transcrip-
tional regulation of HBD2 in response to LPS.
Methods
Cell lines and culture
The human embryonic kidney cell line, HEK293,
(ECACC-85120602) was obtained from the European
Collection of Cell Cultures. Cells were cultured at 37°C in
5% CO2 in Eagle's minimal essential medium (EMEM,
Biowhittaker) supplemented with 10% fetal calf serum
(FCS), 1% L-glutamine, 1% penicillin/streptomycin, 1%
NEAA (Gibco-BRL). The type II-like human lung epithe-
lial cell line A549, (European Collection of Cell Cultures,
Porton Down, UK) were cultured in Ham's F12 (Gibco-
BRL), 10% FCS, 1% penicillin/streptomycin. Prior to ago-
nist treatment, cells were washed with serum-free EMEM/
F12 and placed under serum-free conditions or in serum
containing 1% FCS for LPS stimulation experiments,
including control conditions.
Reverse Transcription (RT)-PCR
RNA isolation and cDNA synthesis were performed as pre-
viously described [19]. The integrity of RNA extraction
and cDNA synthesis was verified by PCR by measuring the
amounts of GAPDH cDNA in each sample using GAPDH-
specific primers to generate a 211 bp product. PCR reac-
tions were performed using standard conditions [19] with
50 pmol each of gene-specific primers (Table 1). After an
initial step of 95°C for 5 min, thermocycling conditions
were 35 cycles of 95°C for 30 sec, 55°C (TLR4 or CD14)
or 58°C (MD2, Mal and GAPDH) for 30 sec and 72°C for
1 min per kb, followed by a final extension step of 72°C
for 10 min. The more abundant GAPDH was amplified
using 25 cycles. Control PCR reactions using an RNA tem-
plate failed to generate any products. Products were
resolved on 1.5% TBE agarose gels containing 0.5 µg/ml
ethidium bromide (Sigma) and images were captured
using the GeneGenius Gel Documentation and Analysis
System (Syngene), analysed by densitometry and com-
pared in a semi quantitative manner using ImageMaster®Respiratory Research 2005, 6:116 http://respiratory-research.com/content/6/1/116
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TotalLab Software (Amersham Pharmacia, Amersham,
UK). The ratio of PCR fragment intensities of HBD2 rela-
tive to GAPDH was determined. All expression values
were verified by at least two independent RT-PCRs.
IL-8 Production
Cells (1 × 105) were left untreated or stimulated with LPS
from Pseudomonas aeruginosa 01, human recombinant
TNF-α or IL-1β (R&D systems). IL-8 protein concentra-
tions in the cell supernatants were determined by sand-
wich ELISA (R & D Systems, U.K.). All assays were
performed in duplicate or triplicate a minimum of three
times.
Preparation of membrane and cytosolic protein extracts
Cells were suspended in 1 ml ice-cold PBS and pelleted by
centrifugation at 10,000 rpm for 5 min at 4°C. Superna-
tant was removed and the pellet resuspended in 100 µl
hypotonic buffer A (5 mM Tris (pH 6.8), 2 mM EDTA, leu-
peptin 5 µg/ml, pepstatin 0.7 µg/ml, benzamidine 5 µg/
ml, PMSF 1 mM)(Sigma, Ireland). Cellular components
were separated by ultracentrifugation at 55000 rpm × 20
min at 4°C. Supernatant, which constituted cytosolic and
nuclear fractions, was removed and stored at -20°C. The
pellet consisting of the membrane fraction was resus-
pended in hypotonic buffer B (20 mM Tris HCl pH 6.8%,
150 mM NaCl, 10 mM EDTA, 1 mM EGTA, 1% Triton
X100, leupeptin 5 µg/ml, pepstatin 0.7 µg/ml, benzami-
dine 5 µg/ml, PMSF 1 mM) by forcing the pellet through
a 22 G needle 5–8 times. Protein concentrations of
extracts were determined by the method of Bradford, and
stored at -20°C.
Western Blot analysis
Extracts (10 µg of protein) were separated by electro-
phoresis on 10% SDS-polyacrylamide gels and transferred
to nitrocellulose, blocked with 0.2% I-Block (Tropix, MA)
and PBS containing 0.1% Tween-20 (Sigma, Ireland).
TLR4 protein was detected using rabbit anti-TLR4 (sc-
10741 Santa Cruz Biotechnology, diluted 1:200), horse-
radish peroxidase-conjugated anti-rabbit IgG (Tropix,
MA) and chemiluminescent LumiGlo Reagent A and Per-
oxide Reagent B (New England Biolabs) according to the
manufacturer's instructions.
Laser Scanning Cytometry
For analysis by laser cytometry, 5 × 104cells/well were
seeded in 8 well chamber slides (Nunc). Slides were fixed
in methanol (AnalaR) for 5 minutes and labelled with
goat anti-HBD-2 antibody (a gift from Dr Paul McCray,
University of Iowa, Iowa City, IA, USA) 1:100 dilution) or
isotype control (1:1000 dilution of 1 mg/ml stock of iso-
type goat IgG) and incubated at 4°C in the dark for 30
min. Slides were washed three times in PBS and probed
with 1:10 dilution of anti-goat IgG fluorescein isothiocy-
anate (FITC, Dako, Glostrup, Denmark) at 4°C in the dark
for 30 min. The washing step was repeated and cells were
permeabilised in a 1:1 ratio of permeabilisation solution
(Dako) and 0.2 µg/ml solution of propidium iodide (PI,
Molecular Probes, Leiden, The Netherlands). Slides were
washed in PBS and HBD-2 expression was quantified on a
CompuCyte laser scanning cytometer (CompuCyte, Cam-
bridge, MA, USA). Cellular fluorescence of at least 5 × 103
cells was measured by laser scanning cytometry. Fluores-
cence excitation was provided by a 488 nm laser line.
Orange (PE) and green (FITC) fluorescence were meas-
ured at 588 +/- 10 nm or 530 +/- 20 nm, respectively. The
threshold contour was set on scatter or orange to detect all
cells as appropriate. Artificially contoured debris was
gated out based on contour size. Aggregated cells were
gated out using an algorithm in the LSC software that
finds and marks multiple cells. Individual TLR4 or HBD-
Table 1
Gene (Accession No.) Primers (5'-3') Bases Product Size
TLR4 (NM_003266)
F AGATGGGGCATATCAGAGC 569–587 481 bpa
R GTCCATCGTTTGGTTCTGG 1068–1050
CD14 (NM_000877)
F TACTCCCGCCTCAAGGAA 459–476 197 bp
R GCTTGGGCAATGCTCAGT 655–638
MD2 (NM_000877)
F GCAACTCATCCGATGCA 95–112 225 bp
R CATCAGATCCTCGGCAAA 319–302
HBD2 (NM_AF071216)
F GGTATAGGCGATCCTGTTACC TGC 2688–2709 202 bp
R TCATGGCTTTTTGCAGCA TTTTGTTC 4542–4567
GAPDH (BC004109)
F AACTCTGGTAAAGTGGAT 122–138 211 bp
R TACTCAGCGCCAGCATCG 333–316
a bp, base pairsRespiratory Research 2005, 6:116 http://respiratory-research.com/content/6/1/116
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2-expressing cells were identified and quantified using
CompuCyte software on the basis of integrated green flu-
orescence reflecting binding of anti-goat FITC antibody.
Transfection and reporter gene studies
Cells (1.5 × 105) were transfected with plasmid DNA
(dominant negative (∆) Mal (Mal P/H), ∆MyD88, ∆TLR4,
MD2, wild type TLR4 or CD4-Toll plasmid) and/or 1 µg
HBD2 promoter-linked luciferase reporter plasmid [20]
using TransFast (Promega) according to the manufac-
turer's instructions. ∆MyD88 contains only a functional
TIR domain and lacks the death domain required for
downstream signaling, while Mal P/H is a dominant neg-
ative version of Mal with a proline to histidine point
mutation in box 2 of the TIR domain. ∆TLR4 lacks an
intracytoplasmic signaling domain and CD4-Toll is a con-
stitutively active chimera of the extracellular domain of
CD4 fused to the transmembrane and cytosolic domains
of TLR4 [21]. Uniform transfection efficiencies were
achieved by measuring expression from co-transfected
luciferase or β-galactosidase expression plasmids, as
appropriate. initially optimizing transfection conditions
using a constitutive luciferase expression vector, pGL3-
control (Promega). In all experiments, equal amounts of
LPS-induced IL-8 and HBD2 expression in A549 and HEK293 cells Figure 1
LPS-induced IL-8 and HBD2 expression in A549 and HEK293 cells. (A) A549 or HEK293 cells (3 × 105/ml) were left untreated 
(control) or stimulated for 24 h with LPS (10 or 50 µg/ml), IL-1β (100 ng/ml) or TNFα (10 ng/ml). Levels of IL-8 in supernatants 
were measured by ELISA and values are expressed as ng/ml. Assays were performed in duplicate a minimum of three times. 
Values are expressed as mean+/- S.E. (n = 3). (B) Total RNA was extracted from A549 or HEK293 cells, reverse transcribed 
into cDNA and used as a template in PCR reactions using HBD2 gene-specific primers. Products were electrophoresed in 1.5% 
TBE agarose gels containing 0.5 µg/ml ethidium bromide and visualized under UV. + represents positive control PCR reaction 
and lanes 1–4 represent untreated cells and cells stimulated for 24 hours with LPS (10 µg/ml), IL-1β (100 ng/ml) or TNFα (10 
ng/ml), respectively. Gels are representative of three independent experiments using cultures from different time points.
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empty vector plasmid DNA was used in control cells, such
that the total amount of transfected DNA remained con-
stant. After 48 h cells were lysed with Reporter Lysis Buffer
(1×) (Promega) (300 µl/well), protein concentrations
were determined, and reporter gene activity was quanti-
fied by luminometry (Wallac Victor2, 1420 multilabel
counter, Turku, Finland) using the Promega luciferase
assay system according to the manufacturer's instructions.
Statistical analysis
Data were analyzed with GraphPad Prism 3.0 software
package (GraphPad Software, San Diego, CA). Results are
expressed as mean ± S.E. and were compared by Mann-
Whitney test. Differences were considered significant
when the P value was ≤ 0.05.
Results
A549 cells respond to LPS with production of IL-8 and up 
regulation of HBD2
Signaling via TLR4 by LPS activates NF-κB and upregulates
a variety of pro-inflammatory genes, including IL-8. We
investigated LPS responsiveness in A549 and HEK293
cells using IL-8 protein production as a surrogate of LPS
responsiveness. Figure 1A shows that A549 cells dose-
dependently induced IL-8 protein expression in response
to stimulation with LPS to levels similar to those induced
by IL-1β. In contrast HEK293 cells failed to induce IL-8
expression in response to LPS, but did respond to IL-1β or
TNFα stimulation with increased IL-8 expression.
We next investigated the effect of LPS stimulation on
HBD2 gene expression in both cells lines. Compared to
untreated cells, LPS induced HBD2 expression at both 10
and 50 µg/ml in A549 cells (Figure 1B). Densitometric
Characterization of A549 and HEK293 cell lines Figure 2
Characterization of A549 and HEK293 cell lines. (A) Duplicate samples of total RNA was extracted from 1 × 106 HEK293 
(HEK) and A549 cells, reverse transcribed into cDNA and used as a template in PCR reactions using TLR4, Mal, CD14, MD2 
and GAPDH gene-specific primers. Products were electrophoresed in 1.5% TBE agarose gels containing 0.5 µg/ml ethidium 
bromide and visualized under UV. (B) Western blot analysis of membrane (mem) and cytosolic (cyt) extracts (10 µg) from 
A549 and HEK293 cells probed with an anti-TLR4 antibody. Data are representative of three separate experiments. (C) For 
fluorescence microscopy, A549 cells (2 × 104) were grown in chamber slides, Fc-blocked and labelled with anti-TLR4 (clear) or 
isotype control antibodies (solid) and fluorophore-conjugated detection antibodies. TLR4 expression was quantified by laser 
scanning cytometry.
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analysis quantified these increases to be 2- and 3.6-fold,
respectively. IL-1β was used as a positive control and
increased HBD2 expression over 30-fold. There was no
response to LPS in the HEK293 cells however both IL-1β
and TNFα did up regulate HBD2 by a factor of 1.8 and 1.5
respectively.
Airway epithelial cells express TLR4 on the cell surface
We characterized the HEK293 cell line to determine
whether it lacked a critical factor for LPS responsiveness.
RTPCR revealed that the HEK293 cells, similar to the
A549 cells, express TLR4, Mal, and CD14 mRNA but
unlike the A549 cells do not express MD2 mRNA (Figure
2A). MD2 is a secreted protein who's interaction with LPS
and CD-14 is necessary for the cellular response to LPS
[22]
We performed western immunoblotting of cytosolic and
membrane fractions from HEK293 and A549 cells to
detect TLR4 protein expression. Figure 2B shows that TLR4
was present in both fractions from the A549 cells but was
not evident in membrane fractions isolated from HEK293
cells. Next we quantified cell surface expression of TLR4
on A549 by fluorescence microscopy. In accord with the
findings of Monick et al [17] but in contrast to Guillot,
[23] we detected TLR4 on the surface of A549 cells (Figure
2C).
LPS-induced HBD2 gene and protein expression in A549 
cells requires TLR4
Next the role of TLR4 in LPS-induced regulation of HBD2
(Figure 3A) in A549 cells was investigated. Compared to
untreated cells (lane 1), LPS increased HBD2 expression at
24 h (lane 5). This effect was blocked by pre-treatment
with a TLR4 neutralizing antibody (eBioscience, Clone
HTA125, Cat. No. 16–9917) (lane 6). An isotype control
antibody had no effect (data not shown). A similar effect
was demonstrated at protein level using laser scanning
cytometry. Stimulation with LPS resulted in a small but
statistically significant increase in HBD2 protein above
control (P < 0.03). This effect is inhibited by pretreatment
with the TLR4 blocking antibody (P < 0.03).
Dominant negative TLR4 inhibits LPS-induced HBD2 
expression in A549 cells
In order to further demonstrate the functional role of
TLR4 in LPS-induced HBD2 expression, we examined the
effect of functionally ablating TLR4 by over expression of
a functionally inactive ∆TLR4 construct in A549 cells.
Because the upregulation of HBD2 by LPS as measured by
semi-quantitative RTPCR was small, albeit statistically sig-
nificant, we further quantified the effect by luciferase
activity of a co-transfected HBD2 promoter-linked luci-
ferase construct (Figure 4). LPS increased both HBD2
mRNA expression (Figure 4A) (P ≤ 0.05) and HBD2 pro-
moter activity (Figure 4B) (P ≤ 0.03) however over expres-
sion of ∆TLR4 significantly inhibited both effects (P ≤
0.05 and 0.03 compared to LPS-treated empty vector-
transfected cells, respectively).
LPS-induced HBD2 expression in A549 cells requires TLR4 Figure 3
LPS-induced HBD2 expression in A549 cells requires TLR4. 
A459 cells were incubated with an isotype control or anti-
TLR4 neutralizing antibody (Anti-TLR4 mAB 5 µg/ml, 30 min) 
then, (A) left untreated or stimulated with LPS (10 µg) for 4 
or 24 hours. Total RNA was extracted, reverse transcribed 
into cDNA and used as a template in PCR reactions using 
HBD2 gene-specific primers. Products were electrophoresed 
in 1.5% TBE agarose gels containing 0.5 µg/ml ethidium bro-
mide and visualized under UV. Gels are representative of 
three independent experiments or (B) left untreated or stim-
ulated with LPS (10 µg) for 24 hours, Fc-blocked and labeled 
with anti-HBD2 (solid) or isotype control antibodies (clear) 
and fluorophore-conjugated detection antibodies. HBD2 
expression was quantified by laser scanning cytometry, as 
described, and data from three experiments is presented. 
HBD2 expression is expressed as Mean Channel Fluores-
cence (MCF) + SEM. (* P < 0.05 vs control, † P < 0.05 vs 
control + LPS).
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TLR4/MD2 transgene expression confers LPS-
responsiveness on HEK293 cells
Having established the inhibitory effect of neutralizing
TLR4 in A549 cells by receptor blockade and over-expres-
sion of a dominant negative construct, we next deter-
mined whether HEK293 cells could be rendered
responsive to LPS by expression of functional TLR4 and
MD2. Expression of CD4/Toll (a constitutively active
TLR4 chimera [21]) and MD2 resulted in significant
induction of the HBD2 promoter (Figure 5A).
Stimulation of HEK293 cells with LPS has no effect on
HBD2 promoter activity (Figure 5B). However transfec-
tion with MD2 and TLR4 transgenes resulted in significant
up regulation of HBD2 promoter activity (P ≤ 0.005 com-
pared to LPS-treated empty vector-transfected cells), an
effect that was further significantly augmented by stimula-
tion with LPS (P ≤ 0.05 compared to untreated MD2/
TLR4-transfected cells).
Expression of dominant negative MyD88 and Mal 
constructs inhibits LPS-stimulated HBD2 expression
Having demonstrated that LPS up regulates HBD2 expres-
sion via TLR4, we went on to elucidate the pathway by
which the signal is transduced to the nucleus. Figure 6
shows that transfection of dominant negative constructs
of the TIR domain containing adaptor proteins MyD88
and Mal alone or in combination dose-dependently
inhibited HBD2 expression in response to LPS. Technical
restrictions of performing transfection experiments in
chamber slides precluded measurement of HBD2 protein
in this part of the study. We would intuitively expect a
similar qualitative effect in HBD2 mRNA and protein
expression, as demonstrated in Figure 3.
Discussion
Induced expression of HBD2 in response to infective and
pro-inflammatory stimuli represents an immediate and
dynamic response by the host epithelium to potential
infection, and the mechanism by which this occurs has
been the subject of much recent investigation. Here we
provide evidence for a critical role for TLR4 in LPS-
induced HBD2 expression in airway epithelial cells. The
∆TLR4 inhibits LPS-induced HBD2 expression in A549 cells Figure 4
∆TLR4 inhibits LPS-induced HBD2 expression in A549 cells. 
A549 cells (1.5 × 105) were transfected with pcDNA3 
(empty vector) or a ∆TLR4 expression plasmid. 24 h post 
transfection, cells were left untreated or stimulated with LPS 
(10 µg/ml) for 24 h. (A) Total RNA was extracted, reverse 
transcribed into cDNA and used as a template in semi-quan-
titative PCR reactions using HBD2 and GAPDH gene-specific 
primers. HBD2 expression was given an arbitrary value of 1 
in control cells. Data are expressed as mean +/- S.E. and are 
obtained from three experiments (* P < 0.05 vs control, † P 
< 0.05 vs control + LPS). (B) Duplicate experiments were 
performed in cells cotransfected with a HBD2 promoter-
linked luciferase reporter plasmid. Cells were lysed and 
reporter gene activity was quantified by luminometry. Data 
are expressed as HBD2 luciferase activity (n = 3). (* P < 0.05 
vs control, † P < 0.05 vs control + LPS)
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TLR4/MD2 transgene expression confers LPS-responsiveness 
on HEK293 cells. HEK293 cells (1.5 × 105) were cotrans-
fected with MD-2 and CD4/Toll or full-length TLR4 expres-
sion plasmids and a HBD2 promoter-linked luciferase 
reporter gene. Equal amounts of the corresponding empty 
vector were transfected into control cells such that the total 
amount of transfected DNA remained constant. Uniform 
transfection efficiencies were confirmed using a β-galactosi-
dase reporter plasmid. 24 hours post transfection, cells were 
left untreated or stimulated with LPS (10 µg/ml) then lysed 
and reporter gene activity was quantified by luminometry. 
Data are expressed as HBD2 luciferase activity. Assays were 
performed in duplicate and are representative of at least 
three separate experiments. (* P < 0.05, ** P < 0.005, *** P < 
0.001 vs control).
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data show that A549 cells respond to LPS with increased
HBD2 gene and protein expression and that these effects
can be blocked by a TLR4 neutralizing antibody or trans-
fection with functionally inactive TLR4, MyD88 or Mal
transgenes. We further implicate TLR4 in LPS-induced
HBD2 expression by demonstrating that expression of
functional TLR4 and MD2 (a co-factor which is unique to
and necessary for TLR4 activity) in HEK293 cells confers
LPS responsiveness to these cells, which can lead to HBD2
induction.
There is some discrepancy in the literature regarding sur-
face expression of TLR4 in A549 cells. Guillot and col-
leagues reported that TLR4 is not expressed on the surface
of A549 cells, but is compartmentalized to the intracellu-
lar compartment [23], while Monick et al. demonstrated
low level surface expression on the same cells [17]. Our
data showed low-level surface expression of TLR4 by LSC,
and TLR4 was also detectable in membrane fractions by
Western blotting. Further evidence of surface expression
comes from the ability to block the receptor with anti-
TLR4 monoclonal antibody. Surface expression of TLR4
has been demonstrated on other respiratory epithelial
cells including human bronchial epithelial cells [24] and
human airway cells in primary culture, where it was found
in a more basolateral distribution. The findings of higher
levels of TLR4 in the cytoplasmic fraction is also relevant,
as internalisation of LPS in A549 cells has been reported
as early as 4 hours after LPS challenge [25], and this inter-
nalisation modulated expression of ICAM-1 and TNF. It
remains unclear whether LPS-TLR4 co-localisation intrac-
ellularly activates the same signalling cascade as at the cell
membrane.
Similar controversy exists regarding the LPS responsive-
ness of A549 cells. Previous studies have suggested that
A549 cells were hyporesponsive to LPS, at doses of up to
100 µg/ml [26-28]. This was not the case in our study.
A549 cells responded to 10 µg/ml LPS with significant up
regulation of both HBD2 and IL-8. One potential reason
for this difference is the type of LPS used. Previous studies
used E. coli LPS. P. aeruginosa is an important respiratory
pathogen, particularly in patients with lung diseases such
as cystic fibrosis (CF) [14]. E. coli, in contrast, is more
important in the gastrointestinal and genitourinary tract,
and as an important cause of septic shock [29]. Mucoid
strains of Pseudomonas have been demonstrated to induce
HBD2 in respiratory epithelia including A549 cells [10].
For these reasons, we used Pseudomonas LPS in our study.
CD-14 is a glycoprotein which, together with TLR4 and
LPS Binding Protein (LBP), forms the LPS signaling com-
plex, and exists in membrane bound and soluble (in
serum) forms. Soluble CD14 is required for LPS signaling
in A549 cells [30], and it is therefore important that LPS
stimulation is performed in the presence of serum, as in
our study.
Different types of LPS differ in their ability to stimulate
cells. Structural differences in LPS, most commonly in the
O-polysaccharide chain [31], may result in different bio-
logical properties. E. coli LPS is highly toxic in its ability to
propagate the systemic inflammatory response syndrome,
principally through activation of monocytes. P. aeruginosa
LPS differs from E. coli LPS both in the O-polysaccharide
side chain and in the Lipid A component, and stimulates
significantly less endotoxic effect [32], but induces sus-
tained airway inflammation in a number of chronic lung
diseases including CF and diffuse panbronchiolitis [33].
Pseudomonas LPS has been shown to be significantly more
potent than LPS from a number of different strains of E.
coli in its ability to stimulate IL-8 and granulocyte colony-
stimulating factor (G-CSF) from respiratory epithelial
cells, including A549 cells [34]. The reason for this is not
clear, but structural differences may determine its process-
ing by the TLR4/MD2 complex, either directly or through
its interaction with the host plasma membrane [35,36].
Basolateral expression of TLR4 has been reported in pul-
monary epithelial cells [37], and this is particularly inter-
esting given that Pseudomonas elastase has been shown to
increase epithelial permeability by its effect on tight junc-
∆MyD88 and ∆Mal inhibit LPS-induced HBD2 expression in  A549 cells Figure 6
∆MyD88 and ∆Mal inhibit LPS-induced HBD2 expression in 
A549 cells. A549 cells (1.5 × 105) were transfected with 
pCDNA3.1 or pDC304 (empty vectors), ∆MyD88 or Mal P/
H expression plasmids as indicated. 24 h post transfection, 
cells were stimulated with LPS (10 µg/ml) for 24 h. HBD2 
expression was measured by semi-quantitative RTPCR. 
Expression in LPS-treated cells was ascribed a value of 100 %. 
Data shown are mean+/- S.E. (n = 3). Regarding amounts of 
transfected DNA, ∆MyD88 + and ++ represent 100 and 200 
ng of dominant negative MyD88 plasmid DNA respectively 
while Mal + and ++ represent 50 and 100 ng of dominant 
negative Mal plasmid DNA respectively. (* P < 0.05, ** P < 
0.01, *** P < 0.005 vs control + LPS)
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tions [38], thereby potentially increasing access of Pseu-
domonas LPS to the basally expressed TLR4.
Previous work by Becker et al [16] in primary human tra-
cheobroncial cells shows a clear increase in HBD2 protein
in response to LPS by western blotting, although another
recent study in primary airway epithelial cells reports low
expression of MD2 limiting LPS responsiveness [18].
MD2 was induced in response to pro-inflammatory
cytokines and bacterial products [18], while MD2 expres-
sion in A549 cells is enhanced along with TLR4 following
infection with RSV [17]. While differences speak to the
limitations of using a cultured cell model, as well as to the
variable responses of cultured primary cells, they also
reinforce the critical importance of both TLR4 and MD2 in
the signalling pathway. A549 cells clearly expressed MD2
and TLR4 and responded to Pseudomonas LPS in our
hands. LPS stimulation resulted in a 5-fold increase in
HBD2 promoter linked activity. The increase in HBD2
protein, though statistically significant, was small in abso-
lute terms raising questions regarding the physiological
significance of LPS-induced epithelial derived HBD2 pro-
duction.
Indirect activation of epithelial cells by proinflammatory
cytokines released by stimulated alveolar macrophages
may be more important at lower concentrations of LPS
[26], while direct stimulation of the epithelial cells may
become important when bacterial load is high, where
TLR4 and MD2 expression is enhanced, or following
internalisation of LPS. The kinetics of the epithelial
response in this and other studies [16,20] may also be rel-
evant, with direct stimulation of the epithelial cells pro-
viding a slower but potentially more sustained release of
HBD2 than that induced by inflammatory mediators.
Indeed, recent studies of cellular cross-talk between epi-
thelial cells and mononuclear cells suggests co-localisa-
tion of these cells may result in a more pronounced
immune response in vivo [25]. Further work using primary
cell culture and co-culture with immune cells mimicking
physiologic conditions is required to clarify the relative
contributions of these cells to HBD2 production in vivo.
The mechanism by which LPS induces HBD2 expression
in respiratory epithelium has not been previously
reported. Indirect evidence for involvement of a TLR came
first from Diamond and colleagues [39] in 1996, who
described CD-14 dependent LPS induced production of
an anti-microbial peptide in bovine tracheal epithelium,
and later from Becker and colleagues, who showed that
HBD2 up regulation in response to LPS in human trache-
obronchial cells was CD14 dependent (33). The GPI-
linked CD14 receptor lacks a cytosolic domain and must
interact with another receptor to transduce its signal to the
nucleus [40]. Transcriptional regulation of HBD2 in
response to LPS has also been shown to involve NF-κB
[41], but the signaling pathway upstream of NF-κB has
not been elucidated. Until recently, TLRs appeared to
share a common signaling pathway downstream of their
TIR domain. It is now known that individual TLRs utilize
different adaptor proteins for signaling, thus conferring
biological specificity in their response to activation by
individual ligands [42,43]. MyD88 is involved in signal-
ing from all TLRs with the exception of TLR3, whilst Mal
is known to have a role in TLR2 and TLR4 intracellular sig-
naling. Our data implicate both MyD88 and Mal in LPS-
induced HBD2 expression and clearly demonstrates the
critical role of TLR4 in LPS induction of HBD2, thus defin-
ing another role for TLR4 in pulmonary host defense.
Along with the previously well-defined functions of TLR4
in induction of a large number of cytokines, chemokines
and adhesion molecules that activate phagocytosis and
the adaptive immune responses, activation of TLR4 in the
epithelium results in a direct microbicidal response via
production of a potent anti-microbial peptide.
Modulation of TLR4 expression in respiratory epithelium
may critically affect the production of HBD2. Risk factors
for respiratory tract infections include increased age and
smoking [44], both of which may affect TLR4 expression.
TLR4 expression in macrophages is reduced in aged mice,
who have a blunted cytokine response to LPS [45]. Ciga-
rette smoke has also been demonstrated to reduce LPS
responsiveness in alveolar macrophages [46]. As LPS is an
active component of cigarette smoke [47], and down reg-
ulation of TLR4 expression by LPS in cigarette smoke, oth-
erwise known as LPS tolerance, may result in impaired
HBD2 production in response to Gram-negative patho-
gens, facilitating colonization and infection. This is the
subject of ongoing work in our laboratory. Similarly, ther-
apies for septic shock aimed at inhibiting LPS signaling by
blockade of the TLR4 receptor [48] may result in increased
susceptibility to nosocomial Gram-negative pneumonia
through impaired HBD2 induction.
HBD2 is an important component of host defense in the
lung. This study defines a critical role for TLR4 in induced
expression of HBD2 in response to LPS and highlights the
potential effect of modulation of TLR4 and the accessory
proteins MyD88 and Mal expression on pulmonary pro-
duction of this potent anti-microbial peptide. We also
provide important information regarding the cellular
responses of A549 cells, a cultured cell model which is
widely used in studies of host defense.
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